Abstract-Pan-cancer analyses attempt to discover similar features among multiple cancers in order to identify fundamental patterns common to cancer development and progression. Pan-cancer analysis at the level of protein expression is particularly important because protein expression is more immediately related to patient phenotype than genomic or transcriptomic data. This study aims to analyze differentially expressed (DE) proteins between early and advanced cases of multiple cancer types through the usage of reverse-phase protein array data. The relevance of these proteins is further investigated by developing predictive models using K-nearest neighbor and linear discriminant analysis classifiers. The results of this study suggest that a pan-cancer analysis may be highly complementary to standard analysis of an individual cancer for identifying biologically relevant DE proteins, and can assist in developing effective predictive models for cancer progression.
possible to find similar patterns at the protein level using pan-cancer DE proteins. This study aims to determine if DE proteins across multiple cancers have roles in cancer progression, and if these proteins can be used to build effective classification models to discriminate between cancer patients in early (stages I and II) and advanced (stages III and IV) stages of disease. The development of well-performing models would suggest that these DE proteins can be considered particularly relevant across multiple cancers, and may be investigated further to confirm that they are biomarkers.
II. METHODS

A. Data
Patient clinical information (n = 3,202) was obtained from The Cancer Genome Atlas (TCGA) for nine types of cancer. Corresponding protein expression data and a pan-cancer protein expression data set were obtained from TCPA. The pan-cancer data set contains normalized protein expression data for all patients in the individual cancer analyses. The nine types of cancer selected were bladder urothelial cancer (BLCA, n=121), breast cancer (BRCA, n=906), colon adenocarcinoma (COAD, n=327), head and neck squamous cell carcinoma (HNSC, n=212), kidney renal clear cell carcinoma (KIRC, n=453), lung adenocarcinoma (LUAD, n=237), lung squamous cell carcinoma (LUSC, n=193), ovarian cancer (OVCA, n=407), and uterine corpus endometroid carcinoma (UCEC, n=346). Patients were grouped based on their stage information, with Stage I and Stage II patients denoted as early stage and Stage III and Stage IV patients as advanced stage. The number of patients in each group for each cancer is shown in Table 1 .
The proteins for which expression data is available were filtered by assessing the antibody validation status associated with each protein, as supplied by TCPA. 113 validated proteins out of the 187 original proteins are analyzed for both individual and pan-cancer analyses. This ensured that the data used for further analysis is from antibodies that have been determined as specific, selective, and reproducible [5] . Figure 1 shows the overall workflow of this study. First, differential expression analysis was performed on both individual cancers and the combined pan-cancer dataset. The two-tailed t-test and Wilcoxon's rank-sum test were used to find DE proteins between the early stage and advanced stage patients, with a significance threshold of  = 0.05. Bonferroni correction was then applied to control the false discovery rate. The relevance of DE proteins for each individual cancer was examined through peer-reviewed literature and the Human Protein Atlas [6] Second, in order to further assess the discriminatory relevance of identified proteins, classification models were developed using K-nearest neighbors (KNN) and linear discriminant analysis (LDA). Several alternative feature sets were used in these models: (i) all proteins; (ii) DE proteins identified through individual cancer analysis; (iii) DE proteins identified through pan-cancer analysis, (iv) proteins selected by mRMR (maximum relevance, minimum redundancy) on individual cancers, and (v) pan-cancer proteins selected by mRMR [7] . The mRMR method was implemented using the FEAST toolbox in MATLAB, and the five highest ranked features were implemented [8] . For the KNN models, alternative numbers of neighbors (K = 1, 3, 5, and 10) were tested.
B. Feature Selection and Classification Modeling
The performance of each predictive model was evaluated Overall, pan-cancer analysis resulted in 56 DE proteins using the rank-sum test and 47 using the t-test. While the individual analysis of each cancer was able to find relevant DE proteins, the pan-cancer analysis was generally able to identify several of the same proteins, as well as additional DE proteins relevant to the progression of each cancer that were not identified in the individual cancer analyses. For example, the pan-cancer DE analysis identified several of the same proteins found by individual analysis for BRCA and HNSC, e.g., p_38_pT180_Y182 in BRCA and MAPK_pT202_Y204 in HNSC. In addition, pan-cancer analysis found Akt and mTOR, two proteins implicated in the progression of both BRCA and HNSC [9, 10] . Neither of these proteins was identified in the individual cancer analyses. In another example, no DE proteins were found for LUAD and LUSC. However, pan-cancer DE analysis identified several proteins, including p38_pT180_Y182, PR, and MYH11, found to be relevant to these cancers [11] [12] [13] [14] [15] . Literature also supports the roles of these proteins in different cancers, with p38_pT180_Y182 linked to BRCA and KIRC, PR linked to BRCA, and MYH11 linked to BRCA and COAD [11, 15, 16] . These results suggest that pan-cancer DE analysis is helpful in identifying biologically relevant proteins that individual analysis may not because of limited sample size, lesser extent of differential expression, or other issues.
Next, the utility of the proteins identified through these alternative analyses was evaluated through predictive modeling. Fig. 2 shows the performance of each model across 10-fold cross-validation. For KNN, the results for K = 1 neighbor are shown, as poorer results were consistently observed for larger values of K tested for this dataset. Overall, several moderately performing models, with mean MCC values ≥ 0.5, were developed and denoted with arrows in Fig.  2 . The LDA models generally outperformed the KNN models, which may be due to the sensitivity of the KNN algorithm to noise [17] . Among alternative feature sets, the 'Pan-Cancer DE' and 'Cancer-specific DE' features appeared to give the highest, or close to highest performance for several cancers (COAD, KIRC, and UCEC). The 'Pan-Cancer mRMR' feature set generally resulted in worse performance than the 'Pan-Cancer DE', 'Cancer-specific mRMR', and 'Cancer-specific' feature sets, suggesting that mRMR is better suited to individual cancers for this type of data. However, for most cancer types, the best performance was observed with 'All Features', suggesting that incorporating more protein expression information improves performance.
Among the cancers for which DE proteins were identified through individual analysis (BRCA, COAD, HNSC, KIRC, OVCA, and UCEC), the 'Pan-Cancer DE' feature set yielded slightly improved performance over the 'Cancer-Specific DE' feature set for all except COAD. In BRCA, HNSC, and UCEC, this feature set also showed improved performance over the mRMR-selected features. These observations indicate that pan-cancer analysis identified relevant proteins that potentially have functional importance in many cancers. This study investigates how pan-cancer analysis can be used to identify significant protein expression patterns across multiple cancers, and how predictive models can be developed using these pan-cancer results. Literature-based assessment of the results indicates that the pan-cancer DE approach successfully identified proteins which are biologically relevant in multiple cancers. Supervised analysis further demonstrated that the identified proteins were useful for developing discriminatory models for pathological stage.
Future research will expand upon these results by investigating other classifiers and feature selection methods, as well as determining an optimal number of features to select through mRMR and other filter-based feature selection methods. The statistical tests with Bonferroni correction were often unable to identify DE proteins for several cancers, which may be due to the conservative nature of the correctional method. An alternative correction method may yield additional relevant proteins.
The current results can be related to a recent pan-cancer study conducted on proteomic and TCGA-provided genomic information using unsupervised clustering analysis [18] . The clusters found in the study revealed proteins similarly expressed across multiple cancers. For example, Cluster V featured large sample populations across multiple cancers, including BRCA and KIRC, with elevated expression levels of MYH11, RICTOR, Caveolin1, and Collagen VI. Our current study compares well against the previous pan-cancer analysis by identifying all of the proteins highlighted in Cluster V as pan-cancer DE proteins. In addition, we apply supervised analysis with LDA and KNN classifiers to explore the performance of alternative feature sets in discriminating between early and advanced stage cancers. However, some differences remain for further investigation. For example, the previous pan-cancer analysis identified HER2 as biologically relevant across multiple cancers, while this study did not. Integrated analyses using multiple data types may yield additional insight into the importance of selected proteins across multiple cancer types, and a more comprehensive understanding of cancer biology.
In conclusion, pan-cancer analyses of protein expression data can lead to a better understanding of the fundamental factors in cancer biology, and can also assist in indicating potential therapeutic strategies and in patient stratification when validated by biologists and clinicians. Proteomic pan-cancer analysis has been limited due to the lack of publicly-available protein expression data. The TCPA initiative is a promising step in this direction. A larger set of proteins for analysis could help identify potential biomarkers and therapeutic targets. Pan-cancer proteomic analysis may also have implications towards therapeutics by suggesting cross application of drugs previously approved for one cancer type to other cancer types. Lastly, this study demonstrated that predictive models for cancer progression could be developed using pan-cancer protein expression data. Using pan-cancer protein expression data to develop models for other targets, including early diagnosis and patient survival, is an important direction for future research, and such models could serve as supportive tools for physicians.
